表紙
市場調査レポート

SBI Biotech Co., Ltd. : 製品パイプライン分析

SBI Biotech Co., Ltd. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 199795
出版日 ページ情報 英文 23 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.32円で換算しております。
Back to Top
SBI Biotech Co., Ltd. : 製品パイプライン分析 SBI Biotech Co., Ltd. - Product Pipeline Review - 2015
出版日: 2015年10月30日 ページ情報: 英文 23 Pages
概要

SBI Biotech Co., Ltd. は、生命科学に基盤を置くバイオベンチャー企業で、免疫細胞治療のための薬剤や、癌やB細胞慢性リンパ性白血病、自己面寝機疾患、そしてアレルギーの治療のための機能性食品の研究・開発に取り組んでいます。

当レポートでは、SBI Biotech Co., Ltd.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

SBI Biotech Co., Ltd.の基本情報

  • SBI Biotech Co., Ltd.の概要
  • 主要情報
  • 企業情報

SBI Biotech Co., Ltd.:R&Dの概要

  • 主な治療範囲

SBI Biotech Co., Ltd.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

SBI Biotech Co., Ltd.:パイプライン製品の概況

  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

SBI Biotech Co., Ltd.:薬剤プロファイル

  • GNKS-356
  • SBI-3150
  • SBI-9674
  • Small Molecule to Inhibit Cdc7/ASK for Oncology

SBI Biotech Co., Ltd.:パイプライン分析

  • 標的別
  • 分子タイプ別
  • 作用機序別

SBI Biotech Co., Ltd.:休止中のプロジェクト

SBI Biotech Co., Ltd.:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • GNKG-168

SBI Biotech Co., Ltd.:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07722CDB

Summary

Global Markets Direct's, 'SBI Biotech Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the SBI Biotech Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of SBI Biotech Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of SBI Biotech Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of SBI Biotech Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the SBI Biotech Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate SBI Biotech Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of SBI Biotech Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the SBI Biotech Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of SBI Biotech Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of SBI Biotech Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of SBI Biotech Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • SBI Biotech Co., Ltd. Snapshot
    • SBI Biotech Co., Ltd. Overview
    • Key Information
    • Key Facts
  • SBI Biotech Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • SBI Biotech Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • SBI Biotech Co., Ltd. - Pipeline Products Glance
    • SBI Biotech Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • SBI Biotech Co., Ltd. - Drug Profiles
    • GNKS-356
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBI-3150
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SBI-9674
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Cdc7/ASK for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • SBI Biotech Co., Ltd. - Pipeline Analysis
  • SBI Biotech Co., Ltd. - Pipeline Products by Target
  • SBI Biotech Co., Ltd. - Pipeline Products by Molecule Type
  • SBI Biotech Co., Ltd. - Pipeline Products by Mechanism of Action
  • SBI Biotech Co., Ltd. - Dormant Projects
  • SBI Biotech Co., Ltd. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • GNKG-168
  • SBI Biotech Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • SBI Biotech Co., Ltd., Key Information
  • SBI Biotech Co., Ltd., Key Facts
  • SBI Biotech Co., Ltd. - Pipeline by Indication, 2015
  • SBI Biotech Co., Ltd. - Pipeline by Stage of Development, 2015
  • SBI Biotech Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • SBI Biotech Co., Ltd. - Out-Licensed Products in Pipeline, 2015
  • SBI Biotech Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • SBI Biotech Co., Ltd. - Preclinical, 2015
  • SBI Biotech Co., Ltd. - Pipeline by Target, 2015
  • SBI Biotech Co., Ltd. - Pipeline by Molecule Type, 2015
  • SBI Biotech Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • SBI Biotech Co., Ltd. - Dormant Developmental Projects,2015
  • SBI Biotech Co., Ltd. - Discontinued Pipeline Products, 2015
  • SBI Biotech Co., Ltd., Subsidiaries

List of Figures

  • SBI Biotech Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • SBI Biotech Co., Ltd. - Pipeline by Top 10 Target, 2015
  • SBI Biotech Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • SBI Biotech Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top